Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Deputy Director, Yale Cancer Center; Chief of Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Assistant Dean for Translational Research, Yale School of Medicine; Program Director, Master of Health Science - Clinical Investigation Track (MHS-CI)
Yale Cancer Center-Advanced Training Program for Physician-scientists (YCC-ATPP)
Program Directors
- Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies. Learn more about Dr. Herbst >> Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs. He has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib), which have
... United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)
Dr. Lieping Chen is an immunologist interested in basic T cell biology, cancer immunology, and translational research to develop new treatments for human diseases including cancer. Prior to joining Yale, he was a faculty member at Johns Hopkins University School of Medicine and Mayo Clinic, and a scientist in Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Chen has published over 400 peer-reviewed research articles. His work in the discovery of the PD-1/PD-L1 pathway for cancer immunotherapy was cited as the #1 breakthrough of the year by Science magazine in 2013. He is a member of the National Academy of Sciences and a fellow of the American Association for Cancer Research.
Executive Committee
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Deputy Director, Yale Cancer Center; Chief of Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Assistant Dean for Translational Research, Yale School of Medicine; Program Director, Master of Health Science - Clinical Investigation Track (MHS-CI)
Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies. Learn more about Dr. Herbst >> Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs. He has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib), which have... United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)
Dr. Lieping Chen is an immunologist interested in basic T cell biology, cancer immunology, and translational research to develop new treatments for human diseases including cancer. Prior to joining Yale, he was a faculty member at Johns Hopkins University School of Medicine and Mayo Clinic, and a scientist in Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Chen has published over 400 peer-reviewed research articles. His work in the discovery of the PD-1/PD-L1 pathway for cancer immunotherapy was cited as the #1 breakthrough of the year by Science magazine in 2013. He is a member of the National Academy of Sciences and a fellow of the American Association for Cancer Research.Arthur H and Isabel Bunker Professor of Medicine (Hematology) and Professor of Pathology; Director, DeLuca Center for Innovation in Hematology Research, Yale Cancer Center; Assistant Medical Director CRSL, Yale Cancer Center; Chief, Yale Cancer Center, Division of Translational Hematology
Dr. Halene is a physician-scientist who received her MD degree at Eberhardt-Karls-University in Tübingen, Germany. She subsequently completed a postdoctoral fellowship in the laboratory of Donald B. Kohn at CHLA in Los Angeles and her residency in internal medicine in the traditional program at Yale New Haven Hospital. She completed her fellowship in hematology/oncology at Yale and joined the ladder faculty at YSM as an assistant professor in 2010. At that time she was also named director of the Hematology Tissue Bank for Yale Cancer Center. She was promoted to associate professor in 2016 and subsequently served as interim chief of the Section of Hematology prior to her appointment as chief of that section in 2020. Her laboratory studies hematopoiesis and myelopoiesis and in particular how mutations in splicing factors and perturbations in RNA modifications contribute to... Professor of Medicine (Hematology); Director, Hematology/Oncology Fellowship Program; Chief, Classical Hematology Program
Dr. Alfred Ian Lee is Professor of Medicine (Hematology) and Program Director for the hematology/oncology fellowship program. He received his MD/PhD from the Yale School of Medicine in 2004. Dr. Lee completed residency in internal medicine at Brigham & Women’s Hospital, where he served as Chief Medical Resident, followed by a fellowship in hematology/oncology at Dana-Farber Cancer Institute. His primary academic interests are classical hematology, thrombosis, and medical education. He has received such honors as the Charles W. Bohmfalk Prize for teaching in the basic sciences, the Leah M. Lowenstein Award for excellence in the promotion of humane and egalitarian medical education, the Yale Cancer Center Award for Mentorship Excellence, and the David J. Lefell Prize for Clinical Excellence.
Additional Information:
Current YCC-ATPP Fellows
Instructor of Medicine (Medical Oncology)
Dr. Jeremy B. Jacox, MD, PhD, is an Instructor in the Department of Medicine (Medical Oncology) at Yale School of Medicine and a Medical Oncologist at Smilow Cancer Hospital. He earned his bachelor’s degree from MIT before pursuing his MD and PhD at Yale University School of Medicine. Under the mentorship of Dr. Ruslan Medzhitov, Dr. Jacox completed his doctoral studies in immunobiology, focusing on how intracellular circuits based on growth factors regulate macrophage and fibroblast interactions in both homeostasis and melanoma. His work was supported by a Ruth Kirchstein F30 NRSA Fellowship from the National Cancer Institute, and his PhD dissertation work awarded with Distinction and the MD/PhD Prize from Yale. Dr. Jacox completed his residency in Internal Medicine at Yale New Haven Hospital through the Physician-Scientist Training Program and continued his... Hospital Resident
Hometown: Kingsville, TX Medical School: University of California San Francisco Undergraduate: Harvard College Professional Interests: Surgical oncology, Healthcare Economics, Global Health, Health Disparities, Medical device/diagnostics.Hobbies: Ballroom Dancing, Basketball, Running, Playing Piano
2019-2021 YCC-ATPP T32 Fellows
Assistant Professor Adjunct; Heme-Onc Medicine Fellow, Medical Oncology
2020-2022 YCC-ATPP T32 Fellows
Associate Research Scientist; Heme-Onc Medicine Fellow, Medical Oncology